Structure and Function of the LPLA2/LCAT Acyltransferase Family

LPLA2/LCAT 酰基转移酶家族的结构和功能

• 批准号: 9174909
• 负责人: John Tesmer
• 金额: $ 48.34万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-11-04 至 2017-08-13
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9174909
• 关键词: Active Sites; Acyltransferase; Address; Adverse effects; Affect; Alveolar Macrophages; Amiodarone; Anti-Arrhythmia Agents; Apolipoprotein A-I; Atherosclerosis; Autoimmune Diseases; Binding; Biological Assay; Biological Response Modifier Therapy; Catabolism; Catalysis; Cations; Cholesterol; Cholesterol Esters; Clinical; Complex; Cryoelectron Microscopy; Crystallization; DNA Sequence Alteration; Development; Disease; Electron Microscopy; Engineering; Enzymes; Eye diseases; Family; Fishes; Future; Glycerophospholipids; Goals; Hereditary Disease; High Density Lipoproteins; Human; Image; Infusion procedures; Kidney Failure; Knowledge; Lead; Learning; Ligands; Lipase; Lipids; Lipoprotein (a); Lipoprotein Binding; Liposomes; Liver; Maps; Membrane; Modeling; Molecular; Mutation; Negative Staining; Outcome Study; Patients; Pharmaceutical Preparations; Phosphatidylcholine-Sterol O-Acyltransferase; Phospholipase A2; Physiological; Plasma Proteins; Play; Positioning Attribute; Proteins; Pulmonary Surfactants; Reaction; Recombinants; Regulation; Reporting; Resolution; Role; Series; Serum; Site-Directed Mutagenesis; Somatic Mutation; Structure; Surface; Testing; Transacylase; Variant; acute coronary syndrome; analog; ataxia telangiectasia mutated protein; base; crystal-8; design; disease phenotype; enzyme replacement therapy; esterase; familial cholesteryl ester deficiency; flexibility; improved; insight; lecithin cholesterol acyltransferase deficiency; lipid metabolism; lipophilicity; macrophage; particle; peptidomimetics; preclinical study; public health relevance; reconstruction; reverse cholesterol transport; small molecule; theories; therapy design

DESCRIPTION (provided by applicant): Lysosomal phospholipase A2 (LPLA2) plays a major role in lipid degradation and is believed to underlie drug-induced phospholipidosis, which commonly occurs in patients taking cationic lipophilic drugs such as the antiarrhythmic amiodarone. Aberrant LPLA2 activity may also be involved in development of autoimmune disease and atherosclerosis. LPLA2 is 50% identical in sequence to lecithin-cholesterol acyltransferase (LCAT), a key enzyme in reverse cholesterol transport from arterial plaque macrophages via high density lipoproteins (HDL). Genetic mutations in LCAT are responsible for Familial LCAT Deficiency (FLD), a devastating disease characterized by low serum cholesterol ester levels and renal failure. There are no reported atomic models for either LPLA2 or LCAT, which do not have significant homology to other proteins of known structure. Thus, the molecular bases for their substrate selectivity, regulation, and disease phenotypes remain poorly understood. In this proposal, we address this critical gap in knowledge via functional analysis of our new 1.8 � crystal structure of LPLA2, determination of the atomic structure of LCAT, imaging LCAT bound to HDL particles by electron microscopy, mapping somatic mutations known to cause genetic disease, and investigating the structural basis for differences in acyl acceptor selectivity. In support of our aims, we provide multiple high resolution structure of LPLA2 in various ligand states, negative stained images of LCAT-HDL complexes, and a low resolution crystal structure of fully glycosylated LCAT. The expected outcome of these studies is a better mechanistic understanding of a structurally uncharacterized family of eukaryotic enzymes that play key roles in lipid metabolism. Our structural and functional studies will help explain the molecular basis for genetic disease and ultimately assist in the design of improved biotherapeutics and small molecule LCAT activators to treat lipid-related disorders such as atherosclerosis and LCAT deficiency.

描述(申请人提供)：溶酶体磷脂酶A2(LPLA2)在脂质降解中起主要作用，被认为是药物引起的磷脂沉积症的基础，通常发生在服用阳离子亲脂性药物的患者，如抗心律失常的胺碘酮。LPLA2活性异常也可能参与自身免疫性疾病和动脉粥样硬化的发生。LPLA2在序列上与卵磷脂-胆固醇酰基转移酶(LCAT)有50%的同源性，LCAT是通过高密度脂蛋白(HDL)从动脉斑块巨噬细胞反向运输胆固醇的关键酶。LCAT基因突变是家族性LCAT缺乏症(FLD)的原因，FLD是一种以低血清胆固醇酯水平和肾功能衰竭为特征的破坏性疾病。目前还没有关于LPLA2或LCAT的原子模型的报道，这些模型与其他已知结构的蛋白质没有显著的同源性。因此，它们的底物选择性、调节和疾病表型的分子基础仍然知之甚少。在这项建议中，我们通过对LPLA2的新的1.8�晶体结构的功能分析、确定LCAT的原子结构、通过电子显微镜对LCAT与高密度脂蛋白颗粒结合的成像、定位已知导致遗传疾病的体细胞突变以及研究酰基受体选择性差异的结构基础来解决这一关键的知识缺口。为了支持我们的目标，我们提供了LPLA2在不同配体状态下的多种高分辨率结构，LCAT-高密度脂蛋白复合体的负染图像，以及完全糖基化的LCAT的低分辨率晶体结构。这些研究的预期结果是更好地从机制上理解结构上没有特征的真核酶家族，这些酶在脂类代谢中发挥关键作用。我们的结构和功能研究将有助于解释遗传病的分子基础，并最终帮助设计改进的生物疗法和小分子LCAT激活剂来治疗脂质相关疾病，如动脉粥样硬化和LCAT缺乏症。